Health Care & Life Sciences » Pharmaceuticals | Catalyst Biosciences Inc.

Catalyst Biosciences Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
3,536.00
275.00
1,750.00
399.00
1,018.00
6
SG&A Expense
50,298.00
29,320.00
13,082.00
19,428.00
22,667.00
33,679
EBIT
47,309.00
29,396.00
11,802.00
19,418.00
21,822.00
33,822
Unusual Expense
-
318.00
1,615.00
156.00
-
-
Non Operating Income/Expense
120.00
13.00
-
2,317.00
261.00
3,767
Interest Expense
53.00
23.00
1,478.00
-
-
-
Pretax Income
46,698.00
29,139.00
14,762.00
16,945.00
21,561.00
30,055
Income Tax
7.00
3,484.00
-
-
-
-
Consolidated Net Income
46,705.00
32,623.00
14,762.00
16,945.00
21,561.00
30,055
Net Income
46,705.00
32,623.00
14,762.00
16,945.00
21,561.00
30,055
Net Income After Extraordinaries
46,705.00
32,623.00
14,762.00
16,945.00
21,561.00
30,055
Net Income Available to Common
46,705.00
32,623.00
14,762.00
16,945.00
25,512.00
30,055
EPS (Basic)
145.78
101.40
49.95
21.75
7.45
2.68
Basic Shares Outstanding
320.40
321.70
295.30
779.20
3,423.90
11,213.90
EPS (Diluted)
145.78
101.40
49.99
21.75
7.45
2.68
Diluted Shares Outstanding
320.40
321.70
295.30
779.20
3,423.90
11,213.90
EBITDA
46,762.00
29,045.00
11,332.00
19,029.00
21,649.00
33,673
Non-Operating Interest Income
784.00
585.00
133.00
-
-
-
Preferred Dividends
-
-
-
-
3,951.00
-

About Catalyst Biosciences

View Profile
Address
611 Gateway Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.catalystbiosciences.com
Updated 07/08/2019
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant. It also develops Anti-C3 CB 2782 for dry age-related macular degeneration.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.